<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02829281</url>
  </required_header>
  <id_info>
    <org_study_id>CEP UNIFESP - 319915</org_study_id>
    <nct_id>NCT02829281</nct_id>
  </id_info>
  <brief_title>Intra-articular Botox Type A Versus Corticosteroids in Knee Osteoarthritis</brief_title>
  <official_title>Intra-articular Botulinum Toxin Type A Versus Corticosteroids: a Clinical Trial in Osteoarthritis of Knees</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Federal University of São Paulo</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Federal University of São Paulo</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Introduction: Osteoarthritis of the knee is a very common disease. However there are few
      treatment options for these patients. Botulinum toxin type A is an option for chronic pain.
      If the investigators prove effectiveness of its use for intra-articular analgesia, Botulinum
      toxin type A can be useful for treat these patients.

      Objective: Compare the effectiveness of the use of intra-articular corticosteroid versus
      Botulinum toxin type A in the treatment of patients with knee osteoarthritis.

      Methods: A prospective controlled randomized double blind studied with three groups (n = 35
      each group) of patients with symptomatic osteoarthritis of the knees receive intra-articular
      medication in a single moment will be undertaken. The three groups will be: Botulinum toxin
      type A Group: patients who receive 100 units of botulinum toxin; hexacetonide of
      triamcinolone Group: patients who receive 40mg of triamcinolone hexacetonide, and saline
      group: patients who receive 2ml of normal saline. Patients will be assessed by evaluators &quot;
      blind &quot; in 4 times during 12 weeks of follow-up with clinical assessment instruments (pain,
      quality of life questionnaire as short form 36 questionnaire) , functional ( WOMAC
      questionnaire) , and ultrasound (quantitative and semi quantitative measure of synovial
      hypertrophy and semi quantitative Power Doppler ) .The following statistical tests will be
      used : Student's t test, Mann - Whitney , chi- square test and ANOVA for repeated measures .
      Will be considered as statistical significance the difference of 5 %.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2016</start_date>
  <completion_date type="Anticipated">December 2016</completion_date>
  <primary_completion_date type="Anticipated">October 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes on Pain</measure>
    <time_frame>Baseline, after 4, 8 and 12 weeks</time_frame>
    <description>Evaluated using the visual analogue scale</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes on Ultrasound parameters</measure>
    <time_frame>Baseline, after 4, 8 and 12 weeks</time_frame>
    <description>quantitative and semi quantitative measure of synovial hypertrophy and semi quantitative Power Doppler</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes on quality of life</measure>
    <time_frame>Baseline, after 4, 8 and 12 weeks</time_frame>
    <description>Evaluated using the Short form 36 questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes on function</measure>
    <time_frame>Baseline, after 4, 8 and 12 weeks</time_frame>
    <description>Evaluated using the WOMAC questionnaire</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">105</enrollment>
  <condition>Knee Osteoarthritis</condition>
  <arm_group>
    <arm_group_label>Botulinum toxin group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive a intervention with joint injection of 100 units of botulinum toxin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Corticosteroid group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will receive a intervention with joint injection of 40mg of triamcinolone hexacetonide (corticosteroid)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Saline Group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients will receive a joint injection of 2ml of normal saline</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Botulinum Toxin Type A</intervention_name>
    <description>Joint injection of Botulinum Toxin Type A</description>
    <arm_group_label>Botulinum toxin group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Triamcinolone hexacetonide</intervention_name>
    <description>Joint injection of triamcinolone hexacetonide</description>
    <arm_group_label>Corticosteroid group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saline</intervention_name>
    <description>Joint injection of Saline</description>
    <arm_group_label>Saline Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age above 50 years

          -  diagnose of knee osteoarthritis using clinics and radiographic criteria

          -  pain for more than 6 months

          -  analogic visual scale among 4 to 8

          -  patients who agree to sign informed consent

        Exclusion Criteria:

          -  secondary osteoarthritis

          -  skin lesion

          -  use of intraarticular corticosteroid in the last 3 months

          -  use of oral corticosteroid in the last 30 days

          -  Kellgren Lawrence I or IV

          -  inflammatory arthritis

          -  neuromuscular disease

          -  use of aminoglycoside antibiotics

          -  metalic prosthesis in knee

          -  peripheric neuropathy

          -  serious cardiovascular or pulmonary disease

          -  serious disorder of coagulation

          -  pregnancy or breastfeeding

          -  infections

          -  use of wheelchair
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jamille G Mendes, MD</last_name>
    <phone>551155764239</phone>
    <email>jamillegmendes@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Rita NV Furtado, MD</last_name>
    <phone>1155764239</phone>
    <email>rvfurtado@hotmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Universidade Federal de Sao Paulo</name>
      <address>
        <city>Sao Paulo</city>
        <state>SP</state>
        <zip>04023-900</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>July 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 4, 2016</study_first_submitted>
  <study_first_submitted_qc>July 7, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 12, 2016</study_first_posted>
  <last_update_submitted>July 7, 2016</last_update_submitted>
  <last_update_submitted_qc>July 7, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 12, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Federal University of São Paulo</investigator_affiliation>
    <investigator_full_name>Jamille Godoy Mendes</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>knee osteoarthritis</keyword>
  <keyword>Intra-articular injection</keyword>
  <keyword>Botulinum Toxin Type A</keyword>
  <keyword>Corticosteroid</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Osteoarthritis, Knee</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Botulinum Toxins</mesh_term>
    <mesh_term>Botulinum Toxins, Type A</mesh_term>
    <mesh_term>onabotulinumtoxinA</mesh_term>
    <mesh_term>abobotulinumtoxinA</mesh_term>
    <mesh_term>Triamcinolone hexacetonide</mesh_term>
    <mesh_term>Triamcinolone</mesh_term>
    <mesh_term>Triamcinolone Acetonide</mesh_term>
    <mesh_term>Triamcinolone diacetate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

